TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of “Moderate Buy” from Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA) has been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $9.00.

HURA has been the subject of several research analyst reports. Citigroup initiated coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They issued an “outperform” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Rodman & Renshaw initiated coverage on TuHURA Biosciences in a report on Wednesday, April 15th. They set a “buy” rating on the stock.

TuHURA Biosciences Trading Down 0.8%

NASDAQ HURA opened at $2.38 on Friday. The stock’s 50-day moving average price is $2.05 and its two-hundred day moving average price is $1.60. The company has a market cap of $151.56 million, a PE ratio of -3.78 and a beta of -0.01. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $4.20.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Research analysts forecast that TuHURA Biosciences will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On TuHURA Biosciences

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of TuHURA Biosciences in the third quarter worth approximately $26,000. JPMorgan Chase & Co. purchased a new position in TuHURA Biosciences during the second quarter valued at approximately $27,000. Invesco Ltd. acquired a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $31,000. Finally, Bank of America Corp DE purchased a new stake in TuHURA Biosciences in the 4th quarter worth approximately $59,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.